In the last trading session, 1.11 million shares of the Sutro Biopharma Inc (NASDAQ:STRO) were traded, and its beta was 1.79. Most recently the company’s share price was $1.05, and it changed around -$0.05 or -4.55% from the last close, which brings the market valuation of the company to $88.58M. STRO currently trades at a discount to its 52-week high of $5.17, offering almost -392.38% off that amount. The share price’s 52-week low was $0.52, which indicates that the current value has risen by an impressive 50.48% since then.
Sutro Biopharma Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.36. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 6 recommended STRO as a Hold, whereas 4 deemed it a Buy, and 1 rated it as Underweight. Sutro Biopharma Inc is expected to report earnings per share of 0 for the current quarter.
Sutro Biopharma Inc (NASDAQ:STRO) trade information
Instantly STRO has showed a red trend with a performance of -4.55% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.1100 on recent trading dayincreased the stock’s daily price by 5.41%. The company’s shares are currently down -42.93% year-to-date, but still up 17.08% over the last five days. On the other hand, Sutro Biopharma Inc (NASDAQ:STRO) is 77.22% up in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $2, which translates to bulls needing to increase their stock price by 47.5% from its current value. Analyst projections state that STRO is forecast to be at a low of $2 and a high of $2.
Sutro Biopharma Inc (STRO) estimates and forecasts
The year-over-year growth rate is expected to be -24.03%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 11.61M in revenue for the current quarter. 9 analysts expect Sutro Biopharma Inc to make 11.54M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 13.01M and 25.71M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -10.77%. Forecasts for the next quarter put sales growth at -55.10%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -4.05%. Sutro Biopharma Inc earnings are expected to increase by 30.93% in 2025, but the outlook is positive 32.32% per year for the next five years.
STRO Dividends
Sutro Biopharma Inc’s next quarterly earnings report is expected to be released in June.
BLACKROCK INC., with 8.5082% or 6.91 million shares worth $20.25 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 2.42 shares worth $2.54 million, making up 2.86% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 2.13 shares worth around $2.24 million, which represents about 2.53% of the total shares outstanding.
